In a nutshell The review summarized results from recent studies that tested pediatric treatments for acute lymphoblastic leukemia (ALL) on adolescents and young adults (AYA). The main conclusion was that the pediatric treatment for AYA patients with ALL will result in better outcomes and survival. Some background Latest ALL treatments have...
Read MoreLeukemia Posts on Medivizor
Liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia
In a nutshell This study aimed to investigate the outcomes for patients with newly diagnosed acute lymphoblastic leukemia who were treated liposomal vincristine and chemotherapy. This study concluded that this combination was safe and effective in these patients. Some background Liposomal vincristine (Marqibo) is a...
Read MoreBendamustine, ofatumumab and ibrutinib treatment for chronic lymphocytic leukemia with high tumor load
In a nutshell This study aimed to investigate if the bendamustine debunking (reducing tumor size) followed by ofatumumab and ibrutinib treatment was safe and effective in patients with chronic lymphocytic leukemia and a high tumor load. This study concluded that this treatment was safe and effective in...
Read MoreNCCN guidelines for children with acute lymphoblastic leukemia
In a nutshell These guidelines aimed to provide information on managing acute lymphoblastic leukemia in pediatric patients. Some background Acute lymphoblastic leukemia (ALL) is the most common cancer in pediatric patients. Advancements in technology have led to improved survival rates for these...
Read MoreSecond-line tyrosine kinase treatment in patients with chronic myeloid leukemia who have failed first-line treatment
In a nutshell This study aimed to investigate second-line tyrosine kinase inhibitor (TKI) treatment in patients with chronic-phase chronic myeloid leukemia (CP-CML) who had failed first-line TKI treatment. This study concluded that these patients have good outcomes with second-line TKI treatment. Some background Tyrosine kinase...
Read MoreEvaluating a method to predict the outcomes of patients with chronic myeloid leukemia treated with imatinib
In a nutshell The study tested whether the EUTOS long-term survival (ELTS) score is efficient to evaluate treatment response in patients with chronic myeloid leukemia (CML), treated with imatinib (Gleevec). The main finding was that ELTS could effectively predict treatment outcomes among such patients in the real world. Some background Initial...
Read MoreHow did availability of ibrutinib change the treatment of chronic lymphocytic leukemia?
In a nutshell The study compared treatments in patients with chronic lymphocytic leukemia (CLL), before and after Ibrutinib (Imbruvica) became available in British Columbia, Canada. The authors found that ibrutinib replaced chemoimmunotherapy for treating relapse and improved survival among patients. Some background Chemoimmunotherapy (CIT) was the...
Read MoreNCCN guidelines for acute myeloid leukemia
In a nutshell These guidelines aimed to provide the latest guidelines on managing acute myeloid leukemia. Some background Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. Recent advances have led to new treatment options for AML such as targeted therapies and low-intensity...
Read MoreMonitoring of asparaginase treatments for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma
In a nutshell This study aimed to investigate the activity of two types of asparaginase drugs in pediatric patients with acute lymphoblastic leukemia or non-Hodgkin lymphoma. This study concluded that this type of treatment needs close monitoring for optimal effectiveness. Some background Asparaginase (ASNase) is a drug used in the treatment of...
Read MoreRisk adjusted treatment of children with non-T cell acute lymphoblastic leukemia
In a nutshell The study reported the outcomes of children with non-T cell acute lymphoblastic leukemia (ALL) treated with risk-adjusted therapy. The main finding was that patients with standard-risk (SR) ALL had improved survival without cancer-related events. Some background ALL-97 was the first clinical trial performed on Japanese children with ALL....
Read MoreCombining obinutuzumab and chlorambucil in unfit patients with chronic lymphocytic leukemia
In a nutshell The study evaluated the effectiveness of combining obinutuzumab (Gazyva) and chlorambucil (Leukeran) (O-Clb) to treat physically unfit patients with chronic lymphocytic leukemia (CLL). The authors found that O-Clb is a safe and effective initial treatment for unfit patients with low-risk CLL in a real-world setting. Some background...
Read MoreEvaluating the risk of infection associated with ibrutinib treatment in patients with chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as chronic lymphocytic leukemia. This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as chronic...
Read More
